IO Biotech, Inc. Board of Directors

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Dr. Marjan Shamsaei Pharm.D.

Dr. Marjan Shamsaei Pharm.D.

Senior VP of Commercial Development & Portfolio Lead

Ms. Amy B. Sullivan M.B.A.

Ms. Amy B. Sullivan M.B.A.

Chief Financial Officer

Prof. Mads Hald Andersen M.D., Ph.D.

Prof. Mads Hald Andersen M.D., Ph.D.

Co-Founder & Scientific Advisor

Mr. Eric Faulkner M.B.A.

Mr. Eric Faulkner M.B.A.

Chief Technical Officer

Dr. Faical Miyara Ph.D.

Dr. Faical Miyara Ph.D.

Chief Business Officer

Mr. Daniel G. Mannix Ph.D.

Mr. Daniel G. Mannix Ph.D.

Senior Vice President of Regulatory Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.